← Back to directory
A
Abingworth
London, United KingdomWebsite ↗
Abingworth is a transatlantic life sciences investment firm that provides capital and development expertise to biotechnology and biopharma companies. It invests across various stages, from seed and early-stage to clinical co-development, aiming to transform cutting-edge science into novel medicines.
Last raised
Oct 2023
2y 9mo ago
Latest fund size
$356M
Clinical Co-Development Co-Investment Fund (CCD-CIF)
AUM
$2B
estimated
Funds raised
Capital this firm has raised, newest first
Clinical Co-Development Co-Investment Fund (CCD-CIF)
Oct 2023
$356M
Abingworth Clinical Co-Development Fund 2 (ACCD 2)
May 2021
$583M
Abingworth Bioventures 8 (ABV 8)
Feb 2021
$466M
Abingworth Clinical Co-Development Fund (ACCD 1)
Jan 2016
$109M
Bioventures VI
Mar 2014
$375M
Abingworth Bioventures III LP (ABVIII)
Jan 2002
$225M
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| cAMPfield Therapeutics | Seed | — | May 2026 | |
| Cytospire Therapeutics | Series A | — | May 2026 | |
| R1 TherapeuticsLead | Series A | $775M | Mar 2026 | |
| Addition Therapeutics | Series A | — | Dec 2025 | |
| Iambic Therapeutics | Growth | $100M | Nov 2025 | |
| Solve Therapeutics | Seed | — | Nov 2025 | |
| Tubulis | Growth | $360M | Oct 2025 | |
| Antares Therapeutics | Seed | — | Apr 2025 |
Sources
Where this data came from